PlainRecalls
FDA Drug Moderate Class II Terminated

Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.

Reported: May 30, 2018 Initiated: May 1, 2018 #D-0823-2018

Product Description

Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.

Reason for Recall

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

Details

Units Affected
1,152 blister cards of 100 capsules each
Distribution
Nationwide in the U.S.
Location
Rockford, IL

Frequently Asked Questions

What product was recalled?
Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.. Recalled by Mylan Institutional, Inc. (d.b.a. UDL Laboratories). Units affected: 1,152 blister cards of 100 capsules each.
Why was this product recalled?
GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination
Which agency issued this recall?
This recall was issued by the FDA Drug on May 30, 2018. Severity: Moderate. Recall number: D-0823-2018.